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INTRANASAL OPIOID COMPOSITIONS 
This application is a continuation of US. application Ser. 
No. 11/674,803, ?led Feb. 14, 2007 noW abandoned, Which is 
a continuation of US. application Ser. No. 10/647,789, ?led 
Aug. 25, 2003 noW abandoned, Which is a continuation-in 
part of US. application Ser. No. 09/790,199 ?led Feb. 20, 
2001 now US. Pat. No. 6,610,271, Which is a continuation 
in-part ofU.S. application Ser. No. 09/569, 125 ?led May 10, 
2000, noW abandoned. The entire disclosure of these appli 
cations is herein incorporated by reference. 
BACKGROUND OF THE INVENTION 
Pain is a major symptom of many diseases, (e.g., cancer, 
arthritis, neurological diseases, heart attacks, etc.). Inad 
equate treatment of pain can lead to depression, anger, fear of 
disease progression and in some extreme cases, suicide. 
Unfortunately, a patient’s non-compliance or failure to 
take medication as prescribed, has been linked to inadequate 
treatment of pain. This is not surprising, since many pain 
treatment regimens involve administering pain medications 
by injection route (e. g., intravenous (IV), intramuscular (IM) 
or subcutaneous injection). The intravenous route is normally 
regarded as one of the most in-convenient routes to administer 
pain medication to achieve rapid pain relief. Intravenous 
administration may cause non-compliance, because not only 
do patients fear getting the injection, but unpleasant experi 
ences such as pain, irritation and infection resulting at the 
injection site may also lead to non-compliance. 
The intranasal route is currently receiving special interest, 
especially in the area of pain management. When medication 
is administered via the intranasal route, the medication is 
applied to the nasal mucosa Where it is absorbed. The exten 
sive netWork of blood capillaries under the nasal mucosa is 
particularly suited to provide rapid and effective systemic 
absorption of drugs. The intranasal route of administration 
should achieve similar dose to plasma concentration (bio 
availability) and e?icacy to that of the intravenous route. 
Intranasal administration of medication provides numer 
ous advantages over the intravenous route. The principal 
advantages of intranasal route are non-invasive delivery, rapid 
drug absorption, and convenience. The intravenous route, 
unlike the intranasal route, requires steriliZation of hypoder 
mic syringes and, in the institutional setting, leads to concerns 
among medical personnel about the risk of contracting dis 
ease if they are accidentally stuck by a contaminated needle. 
Strict requirements for the safe disposal of needles and 
syringes have also been imposed. 
In contrast, intranasal administration requires little time on 
the part of the patient and attending medical personnel, and is 
far less burdensome on the institution than injectable routes. 
There is no signi?cant risk of infection of the patient or 
medical personnel in the institutional setting When dealing 
With the intranasal delivery of medication. 
A second important advantage of intranasal administration 
over intravenous is patient acceptance of the intranasal deliv 
ery route. In some cases, the injections cause burning edema, 
sWelling, turgidity, hardness and soreness. In contrast, intra 
nasal administration is perceived as non-invasive, is not 
accompanied by pain, has no after-effects and produces 
prompt relief in the patient exhibiting pain symptoms. This is 
of particular advantage When the patient is a child. Many, if 
not most, patients experience anxiety and exhibit symptoms 
of stress When faced With hypodermic injections via the IM or 
IV routes. Further, most people have some familiarity With 
nasal sprays in the form of over-the-counter decongestants for 
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alleviating the symptoms of colds and allergies that they or a 
family member have used routinely. Another important con 
sideration is that the patient can self-administer the pre 
scribed dosage(s) of nasal spray Without the need for trained 
medical personnel. 
Among the many medications available to treat pain, opio 
ids (e.g., morphine, methadone, hydromorphone, butorpha 
nol, etc.) play one of the most important roles. The major 
advantage of the opioids is that they have an extensive history 
of use and are much more effective in treating severe pain than 
other classes of medications e.g. aspirin, acetaminophen, ibu 
profen, etc. Another major advantage is that opioids exhibit 
feW adverse effects on organs such as the stomach, liver, or 
kidney, other than very minor problems such as nausea or 
constipation. This is a major bene?t over other medications 
such as aspirin or anti-in?ammatory drugs that may cause 
ulcers, kidney problems, high blood pressure, or liver in?am 
mation. In addition to relieving pain, opioids have other ben 
e?cial effects, such as, for example, peripheral arterial 
vasodilation, When treating heart attacks, provides the bene?t 
of reducing oxygen demand on the heart. 
There are different intranasal opioid formulations knoWn 
in the pharmaceutical arts. HoWever, some intranasal opioid 
formulations have reduced bioavailability at conventional 
doses. These formulations require more pain medication to be 
administered to the patient or else the pain Will be inad 
equately treated. 
Given the problems associated With inadequate treatment 
of pain and patient noncompliance, there is a need for intra 
nasal opioid compositions that have improved bioavailability. 
There is also a need for intranasal compositions that improve 
patient compliance. 
SUMMARY OF THE INVENTION 
In various embodiments, the present invention provides 
intranasal opioid compositions that have improved bioavail 
ability When compared to intranasal prior art opioid compo 
sitions. In other embodiments, the present invention provides 
intranasal opioid compositions that improve patient compli 
ance. 
In one embodiment, the present invention provides a phar 
maceutical composition for intranasal administration to a 
mammal; comprising: an effective amount of an opioid; a 
liquid nasal carrier for the opioid; and one or more sWeeten 
ers, ?avoring agents, or masking agents or combinations 
thereof. 
In another embodiment, the present invention provides a 
pharmaceutical composition having improved bioavailability 
for intranasal administration to a mammal; comprising: an 
effective amount of butorphanol; a preservative-free liquid 
nasal carrier. 
In still another embodiment, the present invention provides 
a pharmaceutical composition having improved bioavailabil 
ity for intranasal administration to a mammal; comprising: an 
effective amount of hydromorphone; a liquid nasal carrier 
having the essential absence of a preservative and the com 
position containing at least one sWeetener, ?avoring agent or 
masking agent. 
In one preferred embodiment, the present invention pro 
vides a pharmaceutical composition for intranasal adminis 
tration to a mammal; comprising: an effective amount of 
hydromorphone; a preservative-free liquid nasal carrier com 
prising sodium chloride, citric acid, Water and at least one 
sWeetener, ?avoring agent or masking agent. 
In still another preferred embodiment, the present inven 
tion provides a method of treating a mammal suffering from 
US 8,198,291 B2 
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pain comprising intranasally administering to the mammal an 
effective amount of butorphanol or hydromorphone; a preser 
vative-free liquid nasal carrier comprising sodium chloride, 
citric acid, Water and at least one sWeetener, ?avoring agent or 
masking agent. 
For a better understanding of the present invention together 
With other and further advantages and embodiments, refer 
ence is made to the following description taken in conjunction 
With the examples, the scope of Which is set forth in the 
appended claims. 
BRIEF DESCRIPTION OF THE FIGURES 
Preferred embodiments of the invention have been chosen 
for purposes of illustration and description, but are not 
intended in any Way to restrict the scope of the invention. The 
preferred embodiments of certain aspects of the invention are 
shoWn in the accompanying ?gures, Wherein: 
FIG. 1 is a graphic representation of the concentration of 
butorphanol in blood plasma versus time after administration 
of the test formulation from a unit-dose spray device (Inven 
tion)) and the administration of the test formulation in a 
multi-dose spray device (Prior Art). 
FIG. 2 is a graphic representation of the data of FIG. 1 over 
a longer time period. 
FIG. 3 is a graphic representation of the concentration of 
hydromorphone in blood plasma versus time for IV, IM and 
intranasal (IN) doses (mean (n:9) Hydromorphone concen 
tration versus time graphs folloWing IV, IM, and IN doses of 
2 mg Hydromorphone HCI (6 hrs after dose). 
FIG. 4 is a graphic representation of the data of FIG. 3 over 
a longer period of time (mean (n:9) Hydromorphone concen 
tration versus time graphs folloWing IV, IM, and IN doses of 
2 mg Hydromorphone HCI (16 hrs after dose). 
FIG. 5 is a graphic representation of the concentration of 
hydromorphone in blood plasma versus time for a group of 
subjects (graph of Hydromorphone concentrations versus 
time folloWing IN doses of 2 mg Hydromorphone HCI to 9 
subjects. 
DETAILED DESCRIPTION OF THE INVENTION 
The invention Will noW be described in connection With 
preferred embodiments. These embodiments are presented to 
aid in an understanding of the present invention and are not 
intended to, and should not be construed to, limit the inven 
tion in any Way. All alternatives, modi?cations and equiva 
lents that may become obvious to those of ordinary skill on 
reading the disclosure are included Within the spirit and scope 
of the present invention. 
In accordance With one embodiment of the present inven 
tion, it has noW been surprisingly found that intranasal phar 
maceutical compositions can be made having improved bio 
availability in terms of plasma opioid levels. These intranasal 
compositions contain an opioid; and a liquid nasal carrier for 
the opioid. For example, it has been unexpectedly discovered, 
among other things, that at least about 10 to about 20% higher 
plasma levels of butorphanol can be achieved by administer 
ing an intranasal formulation from a unit-dose spray device. 
Improved bioavailability includes increases in plasma or 
serum opioid concentration When compared to prior art 
opioid formulations. Preferred increases include, but are not 
limited to, increases of more than 5% to 40% in bioavailabil 
ity of the opioid. 
Opioids as herein include any substance naturally or syn 
thetically derived from opium. Suitable opioids for use in the 
present invention include, but are not limited to, morphine, 
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apomorphine, hydromorphone, oxymorphone, dihydromor 
phine, levorphanol, levallorphan, levophenacylmorphan, nor 
levorphanol, nalorphine, nalbuphine, buprenorphine, butor 
phanol, naloxone, naltrexone, nalmexone, oxilorphan, 
cyclorphan, ketobemidone, fentanyl, sufentanil, alfentanyl, 
or combinations thereof. The most preferred opioids for use 
in the present invention include butorphanol and/or hydro 
morphone. 
The opioid may be in free form or in pharmaceutically 
acceptable salt or complex form. Some examples of pharma 
ceutically acceptable salts of opioids include those salt-form 
ing acids and bases that do not substantially increase the 
toxicity of the compound. Some examples of suitable salts 
include salts of alkali metals such as magnesium, potassium 
and ammonium. Salts of mineral acids such as hydrochloric, 
hydriodic, hydrobromic, phosphoric, metaphosphoric, nitric 
and sulfuric acids, as Well as salts of organic acids such as 
tartaric, acetic, citric, malic, benZoic, glycollic, gluconic, 
gulonic, succinic, arylsulfonic, e.g. p-toluenesulfonic acids, 
and the like. 
Intranasal opioid compositions of the present invention 
include a liquid nasal carrier. As used herein, “liquid nasal 
carrier” includes a solution, emulsion, or suspension 
designed for delivery of the opioid to the nasal mucosa. The 
liquid nasal carrier includes a diluent suitable for application 
to the nasal mucosa. Suitable diluents include aqueous or 
non-aqueous diluents or combination thereof. Examples of 
aqueous diluents include, but are not limited to, saline, Water, 
dextrose or combinations thereof. Non-aqueous diluents 
include, but are not limited to, alcohols, particularly polyhy 
droxy alcohols such as propylene glycol, polyethylene gly 
col, glycerol, and vegetable and mineral oils. These aqueous 
and/or non-aqueous diluents can be added in various concen 
trations and combinations to form solutions, suspensions, 
oil-in-Water emulsions or Water-in-oil emulsions. In the pre 
ferred butorphanol or hydromorphone compositions, the 
diluent is saline or Water. 
The nasal carrier of the present invention may also contain 
excipients such as antioxidants, chemical preservatives, buff 
ering agents, surfactants and/or agents that increase viscosity. 
Antioxidants are substances that prevent oxidation of the 
formulations. Suitable antioxidants for use in the present 
invention include, but are not limited to, butylated hydroxy 
toluene, butylated hydroxyanisole, potassium metabisul?te, 
and the like. 
In some embodiments of the present invention, the com 
position contains a preservative that is chosen in quantities 
that preserve the composition, but do not cause irritation of 
the nasal mucosa. Suitable preservatives for use in some 
embodiments of the present invention include, but are not 
limited to, benZalkonium chloride, methyl, ethyl, propyl or 
butylparaben, benZyl alcohol, phenylethyl alcohol, benZetho 
nium, or combination thereof. Typically, the preservative is 
added to the compositions of the present invention in quanti 
ties of from about 0.01% to about 0.5% by Weight. 
In some embodiments of the present invention, the formu 
lation is preservative-free. As used herein, preservative-free 
includes compositions that do not contain any preservative. 
Thus, the composition does not contain, for example, benZa 
lkonium chloride, methyl, ethyl, propyl or butylparaben, ben 
Zyl alcohol, phenylethyl alcohol, or benZethonium. 
If a buffering agent is employed in the composition, it is 
chosen in quantities that preferably do not irritate the nasal 
mucosa. Buffering agents include agents that reduce pH 
changes. Preferred buffering agents for use in the present 
invention include, but are not limited to, salts of citrate, 
acetate, or phosphate. The most preferred buffers include 
US 8,198,291 B2 
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sodium citrate, sodium acetate, sodium phosphate, and/or 
combinations thereof. Typically, the buffer is added to the 
compositions of the present invention in quantities of from 
about 0.01% to about 3% by Weight. 
When one or more surfactants is employed, the amount 
present in the compositions of the invention Will vary depend 
ing on the particular surfactant chosen, the particular mode of 
administration (e.g. drop or spray) and the effect desired. In 
general, hoWever, the amount present Will be of the order of 
from about 0.1 mg/ml to about 10 mg/ml, preferably about 0.5 
mg/ml to 5 mg/ml and most preferably about 1 mg/ml. 
The pharmaceutical compositions of the present invention 
may include one or more agents that increase viscosity cho 
sen in quantities that preferably do not irritate the nasal 
mucosa and increase nasal retention time. Preferred agents 
that increase viscosity include, but are not limited to, meth 
ylcellulose, carboxymethylcellulose sodium, ethylcellulose, 
carrageenan, carbopol, and/or combinations thereof. The 
most preferred agents used to increase viscosity and increase 
nasal retention time is methylcellulose or carbopol. Typically, 
the agent that increases viscosity is added to the compositions 
of the present invention in quantities of from about 0.1% to 
about 10% by Weight. 
In some embodiments of the present invention, one or more 
sWeetener or ?avoring agents are employed. The sWeetener or 
?avoring agent includes any agent that sWeetens or provides 
?avor to the pharmaceutical composition: The sWeetener or 
?avoring agent Will mask any bitter or bad taste that may 
occur if the pharmaceutical composition drips back into the 
mouth after intranasal administration. By addition of a sWeet 
ener or ?avoring agent to the intranasal composition, any 
barrier that a patient may have to taking the intranasal com 
position because of unpleasant taste is reduced. By adding a 
sWeetener, ?avoring agent or masking agent to the intranasal 
pharmaceutical composition of the present invention, patient 
compliance is enhanced or improved. 
Preferred sWeeteners or ?avoring agents or masking agents 
to use in some embodiments of the present invention include, 
but are not limited to, acacia syrup, anethole, anise oil, aro 
matic elixir, benZaldehyde, benZaldehyde elixir, cyclodex 
trins, compound, caraWay, caraWay oil, cardamom oil, carda 
mom seed, cardamom spirit, compound, cardamom tincture, 
compound, cherry juice, cherry syrup, cinnamon, cinnamon 
oil, cinnamon Water, citric acid, citric acid syrup, clove oil, 
cocoa, cocoa syrup, coriander oil, dextrose, eriodictyon, eri 
odictyon ?uidextract, eriodictyon syrup, aromatic, ethylac 
etate, ethyl vanillin, fennel oil, ginger, ginger ?uidextract, 
ginger oleoresin, dextrose, glucose, sugar, maltodextrin, 
glycerin, glycyrrhiZa, glycyrrhiZa elixir, glycyrrhiZa extract, 
glycyrrhiZa extract pure, glycyrrhiZa ?uidextract, glycyrrhiZa 
syrup, honey, iso-alcoholic elixir, lavender oil, lemon oil, 
lemon tincture, mannitol, methyl salicylate, nutmeg oil, 
orange bitter, elixir, orange bitter, oil, orange ?oWer oil, 
orange ?oWer Water, orange oil, orange peel, bitter, orange 
peel sWeet, tincture, orange spirit, compound, orange syrup, 
peppermint, peppermint oil, peppermint spirit, peppermint 
Water, phenylethyl alcohol, raspberry juice, raspberry syrup, 
rosemary oil, rose oil, rose Water, rose Water, stronger, sac 
charin, saccharin calcium, saccharin sodium, sarsaparilla 
syrup, sarsaparilla compound, sorbitol solution, spearmint, 
spearmint oil, sucrose, sucralose, syrup, thyme oil, tolu bal 
sam, tolu balsam syrup, vanilla, vanilla tincture, vanillin, Wild 
cherry syrup, or combinations thereof. 
Most preferred sWeeteners to use in some embodiments of 
the present invention include, but are not limited to, saccha 
rin, sodium saccharin, xylitol, mannitol, sorbitol, sucralose, 
maltodextrin, sucrose, aspartame, acesulfame potassium, 
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dextrose, glycosides, maltose, sWeet orange oil, dextrose, 
glucose, honey or combinations thereof. Most preferred ?a 
voring agents to use in some embodiments of the present 
invention include, but are not limited to, glycerin, Winter 
green oil, peppermint oil, peppermint Water, peppermint 
spirit, menthol, syrup, or combinations thereof. Most pre 
ferred masking agents do not make contact With the taste 
buds. The preferred masking agent for use in the present 
invention includes, but is not limited to, cyclodextrins, cyclo 
dextrins emulsions, cyclodextrins particles, cyclodextrins 
complexes, or combinations thereof. 
The pharmaceutical compositions of different embodi 
ments of the present invention may of course also include 
additional ingredients, such as pharmaceutically acceptable 
surfactants, co-solvents, adhesives, agents to adjust the pH 
and osmolarity. 
The pharmaceutical compositions of the present invention 
are not limited to any particular pH. HoWever, generally for 
nasal administration a mildly acid pH Will be preferred. The 
pH ranges from about 3 to 6 are preferred, more preferred pH 
ranges are from about 3 to about 5, and most preferred pH 
ranges are from about 4 to about 5. If the adjustment of the pH 
is needed, it can be achieved by the addition of an appropriate 
acid, such as hydrochloric acid, or base, such as for example, 
sodium hydroxide. In the preferred embodiments of the 
present invention, butorphanol or hydromorphone formula 
tions, have a pH of about 5 .0 and a pH of about 4, respectively. 
The pharmaceutical composition in some embodiments of 
the present invention can be made, for example, by mixing the 
opioid With a liquid nasal carrier and/ or a sWeetener, ?avoring 
agent, or masking agent or combinations thereof at room 
temperature under aseptic conditions to form a mixture. In 
other embodiments of the present invention, the mixture is 
?ltered. It Will be understood by those of ordinary skill in the 
art that the order of mixing is not critical, and the present 
invention includes Without limitation mixing of the formula 
tion in any order. 
Pharmaceutical compositions of the present invention can 
be administered intranasally by nasal spray, drop, solution, 
suspension, gel, and the like. In one preferred embodiment, 
the pharmaceutical composition of the present invention is a 
sterile solution or suspension. 
When the pharmaceutical composition is a liquid, pre 
ferred volumes of the liquid are absorbed through the nasal 
mucosa. The preferred volume of the liquid includes volumes 
of from about 0.025 ml to about 2 ml, more preferably, from 
about 0.25 ml to 1 ml, and most preferably from about 0.05 ml 
to about 15 ml in an adult and smaller for children. HoWever, 
the pharmaceutical compositions of the present invention are 
not limited to one particular volume. 
Preferred devices for intranasal delivery of pharmaceutical 
compositions of the present invention are available from, for 
example, Pfeiffer of America of Princeton, N]. and Valois of 
America, Inc. of GreenWich, Conn. These devices are pre 
ferred because they have the capability of consistently deliv 
ering the pharmaceutical composition. These devices are eas 
ily operable by the patient, leave virtually no opioid 
remaining in the device after use and can thereafter be dis 
carded Without concern that others may abuse the opioid or 
other controlled substance. 
The device can be ?lled With single or multidose amounts 
of opioids. Preferably, the device is ?lled With one single dose 
of opioid. In a preferred embodiment, the container holding 
the pharmaceutical composition and its sealing means are 
steriliZable, most preferably, at least parts of the device that 
are in contact With the pharmaceutical composition is con 
structed and assembled in a con?guration that can be steril 
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iZed. Devices With one or more unit-dose(s) can be sterilized 
either before or after packaging, employing methods and 
technology that are Well knoWn in the art. Individual devices 
can be packaged, steriliZed and shipped; alternatively, entire 
shipping and storage packages can be steriliZed at once, and 
the devices removed individually for dispensing, Without 
affecting the sterility of the remaining units. 
The amount of opioid that can be intranasally administered 
in accordance With the composition and methods of the 
present invention Will depend on the particular opioid chosen, 
the condition to be treated, the desired frequency of admin 
istration and the effect desired. As used herein, an effective 
amount of opioid includes that amount effective to achieve 
the relief or palliation of symptoms, condition and/ or diseases 
associated With pain. Some diseases and/or conditions that 
cause pain include, but are not limited to, cancer, arthritis, 
neurological diseases, heart attacks, trauma, childbirth, 
migraines, or surgery. 
Maximal dosage of the pharmaceutical composition of the 
present invention for a mammal is the highest dosage that 
elicits analgesia or anesthesia, Which does not cause undesir 
able or intolerable side effects such as respiratory depression. 
The minimal dose of the opioid is the loWest dose that 
achieves the desired result. In any event, the practitioner is 
guided by skill and knoWledge in the ?eld, and the present 
invention includes Without limitation dosages that are effec 
tive to achieve the pain relieving effect in the mammal. Pre 
ferred doses of opioids for intranasal administration include, 
but are not limited to, hydromorphone HCL from about 0.1 
mg to about 30 mg; butorphanol tartrate from about 0.1 to 
about 10.0 mg; fentanyl citrate from about 5 mcg to about 500 
mcg; methadone HCl from about 0.5 to about 50 mg; oxy 
morphone HCL from about 0.1 mg to about 30 mg; and 
morphine HCL from about 1 mg to about 40 mg. 
The intranasal opioids of the present invention can be used, 
for example, to elicit analgesia or an analgesic response to 
relieve or alleviate pain. The opioids of the present invention 
may also be used to produce anesthesia or an anesthetic 
response Where the mammal experiences loss of feeling or 
sensation, especially loss in pain sensation, to permit the 
performance of surgery or other painful procedures. The 
opioid is administered to a mammal suffering from a condi 
tion and/or disease that require opioid treatment. Mammals 
include, for example, humans, as Well as pet animals such as 
dogs and cats, laboratory animals, such as rats and mice, and 
farm animals, such as horses and coWs. 
EXAMPLES 
The examples beloW demonstrate improved bioavailability 
of illustrative compositions of the present invention When 
delivered from a unit-dose spray device compared to the same 
compositions When delivered from a multi-do se spray device. 
The examples also shoW pharmaceutical compositions that 
include sWeeteners, ?avoring agents, or masking agents or 
combinations thereof, Which can improve patient compli 
ance. 
Example 1 
This example compares bioavailability of a butorphanol 
formulation When administered using a unit-dose or multi 
dose delivery device. The formulation contains 10 mg butor 
phanol tartrate, 6.5 mg sodium chloride, 1.0 mg citric acid, 
0.20 mg benZethonium chloride in puri?ed Water With 1 .2 mg 
sodium hydroxide and hydrochloric acid added to adjust the 
pH to 5.0. The multi-dose sprayer purports by its label to 
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administer 0.1 ml of liquid composition by metering upon 
activation by the user. The formulation had the folloWing 
function and properties When administered to human subjects 
via the Pfeiffer Unitdose Second Generation spray device. 
Administration of a 2 mg dose of butorphanol tartrate pro 
duced a Tmax (hr) of about 0.234 (range about 0.083 to about 
0.333); a Cmax (pg/ml) of about 5230 (range ofabout 2393 to 
about 8478); an AUC(O_t) of about 10661 pg*hr/ml (range of 
about 5351 to about 17722). Administration using the multi 
dose spray pump produced a Tmax of 0.245 hr, a Cmax of 4072 
pg/ml and an AUC(O_t) of 9329 pg*hr/ml. 
The second delivery system employed to administer the 
butorphanol compositions Was a unit-dose disposable intra 
nasal applicator that is commercially available from Pfeiffer 
of America under the designation “Unitdose Second Genera 
tion.” Each of the Pfeiffer spray applicators Was charged With 
suf?cient liquid to deliver a 0.1 mL dose of the butorphanol 
test formulation. The glass containers Were ?lled using a 
pipette under clean conditions, sealed and assembled to the 
applicator. Each of the applicators Was Weighed prior to use 
and after use. Quali?ed medical personnel administered, one 
dose into each nostril, after Which the applicator Was recov 
ered for Weighing. In the case of the unit-dose applicators 
(test formulation), tWo devices Were used for each patient, 
both of Which Were discarded folloWing the post-use Weigh 
ing. The results of these studies of the method and system of 
the invention and the comparative prior art method folloW. 
TABLE I 
Sample Characteristics of Dose Weight Delivery. 
Delivery mean Wt. std. std. 
System N gms dev. error minimum maximum 
Unit-Dose 23 0.206 0.00660 0.00138 0.193 0.223 
Multi-Dose 24 0.180 0.0285 0.00582 0.114 0.220 
Unit-Do se: 
The statistical comparison of dose 1 and dose 2 for the test 
formulation unit dose delivery system Was done using a 
paired t-test. Analysis of the data indicated that the difference 
betWeen the mean, sprays of the tWo applications using the 
Pfeiffer device Was not statistically signi?cant (t:1.0; p:0.3). 
The sample of 23 sprayers (actually 23 sets of 2 sprayers, 
since they Were single-dose) had a mean total dose for tWo 
sprays of 0.206 grams With a standard deviation of 0.00660 
grams. 
Multiple-Dose: 
The total dose dispensed by tWo sprays Was recorded. The 
sample of 24 multi-dose sprayers had a mean total dose for 
tWo sprays of 0. 1 80 grams With a standard deviation of 0.0285 
grams. 
Comparison of Average Total Dose: 
The tWo-sample t-test for the comparison of the unit-dose 
and multi-dose sprayers indicated a statistically signi?cant 
difference betWeen the mean total doses taking into account 
the siZe of the sample. The unit-dose mean total dose Was 
signi?cantly closer to the prescribed target and dose than the 
multi-dose mean total dose (t:4.3; p<0.001). A 95% con? 
dence interval for the difference in means is (0.0140, 0.03 80). 
Comparison of Variability: 
The F test for the comparison of variances revealed that the 
variability in the total doses dispensed by the multi-dose 
sprayer Was signi?cantly higher than the variability in 
Weights dispensed by the unit-dose sprayer (13:18.7; 
p<0.001). The variability in the multi-dose sprayer is 18.6 
times that of the unit-dose sprayer. High variability in dose 
US 8,198,291 B2 
delivery leads to higher rates of adverse drug effects at exces 
sive dose and inadequate treatment if the dose is loW. Both 
consequences harm the patient hence the goal is to precisely 
deliver the prescribed dose. 
Comparison of Each Sprayer to the Standard of 0.2 Grams 
A t-test Was used in each case to compare the observed 
sample mean to the desired Weight of 0.2 grams. The unit 
dose sprayer dispensed a mean total Weight that Was signi? 
cantly higher than the goal of 0.2 grams (t:4.4; p<0.001). A 
95% con?dence interval for the mean total Weight dispensed 
by the unit-dose sprayer is (0.203, 0.209). The multi-dose 
sprayer dispensed a mean total Weight that Was signi?cantly 
loWer than the goal of 0.2 grams (t:3.4; p<0.003). A 95% 
con?dence interval for the mean total Weight dispensed by the 
multi-dose sprayer is (0.168, 0.192). Based on the above, the 
unit-dose delivery system of the test formulation exhibits a 
much higher degree of accuracy in intranasally administering 
the volume of liquid composition corresponding to 0.1 gm: 
+3% vs —10%. 
Bioequivalence 
This example assesses the bioequivalence of a butorphanol 
formulation administered from the unit-dose or multi-dose 
sprayers described above. The test formulation comprises 1 
ml of STADOL NS containing 10 mg butorphanol tartrate, 
6.5 mg sodium chloride, 1.0 mg citric acid, 0.20 mg benze 
thonium chloride in puri?ed Water With 1.2 mg sodium 
hydroxide and hydrochloric acid added to adjust the pH to 
5 .0. The multi-dose sprayer accompanying STADOL NS pur 
ports, by its label, to administer 0.1 ml of liquid. The unit 
dose delivery device delivers 0.1 ml of liquid. 
The second analysis Was to determine Whether the intra 
subject variabilities of the tWo spray devices are equal. The 
study Was initiated With 16 subjects, 15 of Which completed 
the study to provide data for this analysis; one subject 
dropped out after the second period. The folloWing analysis 
considers both raW and normalized data, With the latter stan 
dardized With respect to the dose dispensed. 
For both the raW and normalized data, log transformations 
are applied to the pharmacokinetic endpoints Cmax, AUC 
(00891 ast), and AUC(inf.). A mixed effects model Was con 
sidered for each parameter. Fixed effects for the factors 
sequence (4 levels), period 3 levels) and formulation (2 lev 
els) Were included in the model. Additionally, gender, as Well 
as the interactions betWeen gender and each of sequence, 
period and formulation Was included as a factor in each model 
to determine Whether separate analyses Would be necessary 
for males and females. A total of seven models Were consid 
ered: Tmax, log of raW Cmax values, log of normalized Cmax 
values, log transformed values for raW and normalized AUC 
(last), and log values for raW and normalized AUC(inf.). In all 
cases, the interaction betWeen gender and formulation Was 
not signi?cant, indicating that separate models for males and 
females Were not Warranted. In addition, the lack of signi? 
cance of the effects included in each model indicate that there 
Was no evidence of unequal carryover betWeen the delivery 
system of the prior art and that in one embodiment of the 
present invention. 
The mean levels of butorphanol from analysis of the sub 
ject’ s blood plasma reported in pg/ml are plotted against time 
in FIGS. 1 and 2. The concentration of drug for the unit-dose 
Was unexpectedly higher than that of the multi-dose system. 
The testing for bioequivalence Was done using the method of 
tWo one-sided t-test (as described by Bolton, S., Pharmaceu 
tical Statistics. Marcel Dekker, Inc., NeW York, 1997, pages 
415 ff.). For each parameter, the 90% con?dence interval for 
the ratio of the test unit-dose to reference multi-dose devices 
appear in Table 2 beloW. 
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TABLE 2 
Summag of the tWo one-sided hypothesis tests for PK parameters 
Lower Conf Limit for Upper Conf Limit for 
Parameter Ratio of Test/Reference Ratio of Test/Reference 
Tmax 0.749 1.132 
log (Cmax)* 1.031 1.855 
log (AUClast)* 1.037 1.540 
log(AUCinf)* 1.050 1.461 
log(normCmax)* 0.897 1.5 89 
log(AUClast)* 0.921 1.290 
log(normAUCinf)* 0.937 1.220 
*Note: 
The actual con?dence limits obtained for these parameters have been exponentiated since 
the data Were log-transformed originally. 
Since none of these con?dence intervals for the non-stan 
dardized data are contained in the interval from 0.8 to 1.25, 
the conclusion is that the tWo (test and reference) are not 
equivalent When compared on raW values. For Tmax, the one 
sided t-test for H0: Test/ Reference <0.8 is not rejected. Also, 
the tests of HO: Test/Reference >1.25 are not rejected for any 
of the log-transformed raW values. While the normalization 
by dispensed doses does improve the comparability of the tWo 
devices, tWo of the three parameters fail to reject the null 
hypothesis HO: Test/Reference >1 .25. Bioequivalence is sup 
ported only by the pair of one-sided tests for the normalized, 
log-transformed AUC(inf). Both one-sided t-test for each of 
the seven parameters have been performed at an alpha level of 
0.05. 
The data shoW that the FDA-approved (STADOL NS) 
product that has been sold and dispensed for a number of 
years unexpectedly delivers beloW label strength. The degree 
of variability is also signi?cantly greater than that of the 
method of the invention using the Pfeiffer device. Since the 
test formulation administered from the unit-dose device 
achieves higher drug serum concentration, the small excess in 
unit-dose administration can be further reduced by adjusting 
the volume and/or drug concentration placed in the delivery 
device. Thus, the drug container can actually be ?lled With 
less drug. 
Equality of Variances 
The Pitman-Morgan adjusted F test Was used to compare 
variances of the unit-dose and multi-dose parameters. (See 
ChoW, S-C. and Liu, J-P, Design and Analysis ofBioavail 
ability and Bioequivalence Studies. Marcel Dekker, Inc., 
NeW York (2000)). Since this test could not be generalized to 
the three period design, the ?rst tWo periods of the butorpha 
nol trial Were used, and for the purposes of this analysis, there 
are tWo delivery systems, tWo periods, and tWo sequences. 
The Pitman-Morgan adjusted F test can be used even if the 
period effect is signi?cant, and has a simpli?ed form in the 
absence of period effects. Of the seven PK parameters con 
sidered, only Tmax exhibited a signi?cant period effect. Table 
3 summarizes the results of the tests of equality. The null 
hypothesis is that the variances are equal, and small p-values 
are indicative of a departure from equality. 
TABLE 3 
Summag of the Pitman-Morgan’s ad'usted F tests for PK parameters 
Parameter Pitman-Morgan P Value p-value 
Tmax 0.3 0.6 
log (Cmax) 11.3 0.005 
log (AUClast) 30.1 <0.0001 
log (AUCinf) 15.3 0.002 
log (normCmax) 8.4 0.01 
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TABLE 3-continued 
Summag of the Pitman-Morgan’s ad'usted F tests for PK parameters 
Parameter Pitman-Morgan P Value p-value 
log (AUClast) 23.7 0.0002 
log (nonnAUCinf) 10.7 0.0005 
The tests of equality variances indicate that for all PK 
parameters except Tmax, the variabilities of the two dose 
systems are signi?cantly different, with the unit dose system 
demonstrating much lower variability of drug levels in the 
blood. While the normalization of the Cm“, AUC(last) and 
AUC(inf) parameters somewhat decreased the difference 
between the variances (as evidenced by slightly smaller F 
values), the variances were nonetheless signi?cantly differ 
ent. The variability associated with the unit-dose system was 
smaller than that of the multi-dose system of the prior art, 
which is consistent with the ?ndings of the delivery volume 
weight study. 
From the above, it is apparent that the dose wei ght/ volume 
data is con?rmed by the blood level (pharmacokinetic) analy 
sis. The formulation administered from the multi-dose device 
results in an area under the curve that is 90% of the test 
formulation of the present invention. Thus, the test device 
achieves 10% higher area under the curve and 10% higher 
serum levels as compared to the reference device. This dif 
ference is highly signi?cant from a patient therapy stand 
point. When FDA-prescribed bioequivalence statistical meth 
ods are applied, it is concluded thatithe products as 
administered to the patients are not equivalent. Thus, the 
unit-dose device in one embodiment of the present invention 
provides an unexpected improvement in the intranasal admin 
istration of butorphanol. 
As will be understood by one of ordinary skill in the art, the 
results and conclusions drawn above from the study of the 
intranasal administration of butorphanol can be extended in 
the practice of the invention to other opioids that can be 
administered intranasally in the form of a liquid spray. More 
over, the compositions and methods of the present invention 
can be practiced to the advantage and bene?t of patients, of 
medical facilities and medical professionals, and of society at 
large for the intranasal administration of other opioids and 
controlled substances. 
The formulation substantially as described immediately 
above was prepared but did not contain benZethonium chlo 
ride. This formulation had the following spray pattern func 
tion when sprayed from the Pfeiffer Unitdose Second Gen 
eration device onto an impaction plate from at various 
distances. At a spray distance of 1 cm the spray had an average 
maximum diameter (Dmax) of about 2.3 cm (range 2.2-2.4), 
an average minimum diameter (DMZ-n) of about 2.1 cm (range 
2.0-2.2) and an average ovality of about 1.1 (range of 1.0 to 
1.2; 9.1% RSD). At a spray distance of3 cm the spray had an 
average maximum diameter (Dmax) of about 5 .2 cm (range of 
4.2-6.1), an average minimum diameter (DMZ-n) of about 4.6 
cm (range of 3.8-5.8) and an average ovality of about 1.1 
(range of 1 .0-1.3; 9.2% RSD).At a spray distance of5 cm, the 
spray had an average maximum diameter (Dmax) of about 7.9 
cm (range of 7.0-8.4), an average minimum diameter (DMZ-n) 
of about 7.2 cm (range of 5.8-8.0) and an average ovality of 
about 1.1 (range of 1.0 to 1.2; 6.6% RSD). 
At a spray distance of 1 cm from a detection laser beam, the 
spray has a droplet siZe distribution having a mean Dv10 of 
about 15.45 pm (range of 13.70 to 19.98), a mean Dv50 of 
about 41.46 pm (range of35.74 to 55.67) and a mean Dv90 of 
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about 93.88 pm (range of 69.55 to 117.15). The spray had a 
mean span [(Dv90-Dv10/Dv50)] of about 1.76 (range of 
1.55-1.91). 
At a spray distance of 3 cm, the spray had a droplet siZe 
distribution having a mean Dv10 of about 13.83 pm (range of 
11.84 to 15.68), a mean Dv50 of about 35.29 pm (range of 
29.46 to 41.69) and a mean Dv90 ofabout 90.80 pm (range of 
71.2 to 122.42). The spray had a mean span [(Dv90-Dv10/ 
Dv50)] of about 2.17 (range of 1.92-2.56). 
At a spray distance of 5 cm, the spray had a droplet siZe 
distribution having a mean Dv10 of about 15.82 pm (range of 
14.38 to 17.17), a mean Dv50 of about 32.96 pm (range of 
31.03 to 35.32) and a mean Dv90 ofabout71.85 um (range of 
61.64 to 83.68). The spray had a mean span [(Dv90-Dv10/ 
Dv50)] of about 1.69 (range of 1.50-1.90). 
The formulation had the following function and properties 
when administered to human subjects via the Pfeiffer Unit 
dose Second Generation spray device. Administration of a 
single 2 mg dose of butorphanol tartrate produced a Tmax (hr) 
ofabout 0.25 (range of0.167 to about 0.5); a Cmax (ng/ml) of 
about 2.08 to about 4.68; and an AUC(O_t) of about 7.6 to 
about 11.41 ng*hr/ml. 
Example 2 
Hydromorphone lntranasal Solution 
In accordance with the composition and methods described 
above, hydromorphone HCL (HM HCL) was formulated in a 
liquid composition for use in the practice of one embodiment 
of the invention. HM HCL is a potent mu-receptor agonist 
opiate analgesic with properties similar to morphine. HM 
HCL is chemically similar to morphine, oxymorphone, and 
codeine and shares many of their analgesic and pharmaco 
logical properties. 
HM HCL is a prescription drug narcotic analgesic, more 
commonly known by the trade name of DILAUDID® (Merck 
Index, 1983). Dilaudid (C17Hl9O3NH2O) was discovered by 
theA.G. Knoll chemical ?rm of Ludwigshafen, Germany and 
was the subject ofa 1923 patent. The ?rst literature describing 
the synthesis and testing of this medication appeared in the 
1920’s and it has been used in the clinical management of 
pain since then. The ?rst extensive literature review was pub 
lished in 1933 by the Council on Pharmacy and Chemistry in 
the Journal oflheAmerican MedicalAssocialion (Eddy, N. B. 
Dilaudid (Dihydromorphoninone hydrochloride) J Am Med 
Assoc 1933; 100: 1032-1035). The drug is approved and 
widely accepted in the medical community as a safe and 
effective analgesic. It is presently marketed under the trade 
name Dilaudid® and Dilaudid-HP by Abbott laboratories. 
It is known that HM HCL is subject to hepatic ?rst pass 
metabolism when administered orally or by suppository. 
Thus, when administered intranasally, the effective unit-dose 
can be substantially less as compared to doses administered 
by oral or rectal routes. 
The HM HCL is preferably prepared in the form of a single 
or unit-dose nasal spray for intranasal administration by a 
precision dosage manually activated pump. Each 1 ml of 
nasal spray solution is preferably formulated to contain 10 mg 
HM hydrochloride with 0.2% sodium chloride, 0.2% sodium 
citrate, 0.2% citric acid solution, and sterile water (i.e., water 
for injection, USP), accepted antioxidant concentration and 
buffer in pharmaceutical products. The pH of this formulation 
was approximately pH 4.0. This formulation was used in the 
hydromorphone clinical study below. 
As will be understood by those familiar with the art, do sage 
forms at lower concentrations of hydromorphone can be pre 
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pared for administration based upon the patient’s lower body 
Weight, as in the case of children or adults of substantially 
smaller siZe. The nasal spray solution has a pH in the range of 
from about 3 to about 7, With a pH of about 4-5 being pre 
ferred. 
In a preferred delivery system, each actuation of the nasal 
spray pump delivers 0.1 ml of this 10 mg/ml HM HCL solu 
tion constituting a 1 mg dose. A smaller dose may be admin 
istered to children. The ?lled applicators can be steriliZed by 
methods Well known in the art. The HM HCL nasal spray 
applicators are stored at 15°-30o C. (59°-86o F.) and protected 
from light to provide for maximum shelf life. Since the appli 
cator body is not transparent, visual inspection of the drug 
product for signs of deterioration is not possible and attention 
to the expiration date and storage conditions is important. 
Any expired product is discarded in the appropriate manner. 
An analysis of previous Work describing intranasal (IN) 
administration of narcotics suggested that HM HCL is highly 
likely to have good bioavailability by the IN route in vieW of 
its potency and Water solubility. Extensive revieW of hydro 
morphone literature did not reveal any comparative IV/IM/IN 
concentration versus time or pharmacokinetic data. A proto 
col Was designed to determine the bio-availability of HM 
HCL by the IM and IN routes by comparing the pharmaco 
kinetics of intramuscularly administered HM HCL and intra 
nasally administered HM HCL to HM HCL administered via 
the IV route. Speci?cally, the objectives of this study Were: 
(1) to compare the pharmacokinetics of HM via intranasal, 
intramuscular, and intravenous administration of a 2 mg dose 
of HM HCL; and (2) to evaluate the bioavailability of 2 mg 
HM HCL after intranasal, IM and IV routes of administration 
using a standard three-period, crossover design. 
A formulation of HM HCL for intranasal administration 
Was prepared in the form of a liquid composition at a concen 
tration of 1.0 mg ofHM HCL in 0.1 L. The composition Was 
used to ?ll the required number of single-dose, metered 
sprayers commercially produced and sold by Pfeiffer of 
America, Inc. Each subject received a single spray in each 
nostril for a total of 2.0 mg. A 2.0 mg dose is preferred as 
being Within common, safe and labeled doses prescribed for 
pain management. Commercially available HM HCL (Dilau 
did® for parental administration from Knoll Pharmaceutical 
Company) Was purchased for IlVI/IV administration. 
Investigational Methods 
Nine healthy male subjects betWeen the ages of 22 and 33 
years participated in this inpatient study. Study participants 
Were selected based on inclusion/exclusion criteria, history 
and physical exam, laboratory tests, and other customary 
procedures. Subject demographics Were recorded. These 
included age range: 22-33 years; height range: 168-188 cm; 
Weight range: 70.3-95.3 kg; origin: six Caucasian, tWo Asian, 
one Native American; all Were non-smokers. All nine of the 
subjects completed the study according to the protocol. Each 
of the subjects received 3 doses of 2 mg of HM HCL on three 
separate occasions. No clinically signi?cant protocol viola 
tions occurred during this study. Because the inclusion crite 
ria mentioned abstinence from prescription and non-prescrip 
tion drugs prior to and during the study, any medications 
taken in the 14 days before the study and during the study 
Were noted. 
Clinical Trials 
Study Drug Formulation: HM HCL for intranasal adminis 
tration Was supplied by the University of Kentucky College of 
Pharmacy. HM HCl for intravenous administration Was sup 
plied as Dilaudid® 1 mg/mL for subjects 1, 3, 8, and 9 on the 
?rst day and for subjects 2, 4, 5, 6, 7 on the second study day. 
HM HCl for intramuscular administration Was supplied as 
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Dilaudid® 4 mg/mL for subjects 2, 4, 5, 6 and 7 on ?rst study 
day and for subjects 1, 3, 8 and 9 on the second study day. Free 
base content Was 1.77 mg or 88.7% of stated HM HCl 
strength (from molecular Weights: 321 .8—36.46:285.34, 
285 .34/32 1 .8:88.7%). To summariZe, the dosages for each of 
the three routes of administration Were as folloWs. 
Treatment A: 2.0 mg intravenous HM HCL 
Treatment B: 2.0 mg intramuscular HM HCl; and 
Treatment C: 2.0 mg intranasal HM HCl solution 
Study Drug Administration 
On days 1 and 8, 2.0 mg of HM HCl Was given intrave 
nously or intramuscularly in random order folloWing an over 
night fast. On day 15, 2.0 mg of HM HCI Was given intrana 
sally folloWing an overnight fast (except for Water ad lib). 
Subjects Were not permitted to recline for 4 hours folloWing 
drug administration and remained fasting for 4 hours (until 
lunch) on these study days. 
Meals and snacks prepared by the University of Kentucky 
Hospital Dietetics and Nutrition department Were provided 
for each subject. Subjects Were instructed to eat all of their 
meals. All subjects received identical meals and snacks on 
each of the treatment days, but received different meals on the 
different study days. 
Safety Measures 
Weight, blood pressure, and pulse Were measured prior to 
dosing and at the end of the study. Blood pressure and pulse 
rate Were measured With the subjects seated in an upright 
position before any corresponding blood sample Was col 
lected. Blood pressure and pulse rate Were measured and 
recorded on the same arm throughout the study at 0 (pre-do se) 
and 30 minutes, 1, 2, 4, 8 and 16 hours. 
Clinical Adverse Events 
Spontaneously reported adverse events Were recorded by 
the subjects throughout the study; adverse events Were also 
elicited by non-directed intervieWs. 
Sample Collection 
Blood samples for period I through period III Were col 
lected from each subject according to the folloWing schedule: 
0 (pre-dose), 5, 10, 15,20, 30 and 45 minutes, and 1, 2, 3, 4, 
6, 8, 12 and 16 hours folloWing HM HCl administration. The 
beginning of the IV administration Was considered time Zero. 
After collection, the blood Was centrifuged in a refrigerated 
centrifuge at 40 C. to separate the plasma and the cells and the 
plasma Was transferred to polypropylene tubes. The plasma 
Was stored at approximately —70° C. at the study site until 
shipped to an independent analytical service. The plasma Was 
maintained froZen during shipping and upon arrival at the 
remote analytical facility, the samples Were stored at approxi 
mately —200 C. until analyZed. 
Bioanalytical Methods 
LC/MS/ MS Assay for Hydromorphone 
The sample analysis Was performed by an independent 
service in accordance With established protocols. Concentra 
tions less than 20 pg/mL Were reported as beloW quantitation 
limit (BQL). Samples With concentrations greater than 2,000 
pg/mL Were reanalyZed using a dilution so that the assayed 
concentration Was Within the range of 20 to 2,000 pg/mL. QC 
samples Were also diluted. During the validation, the preci 
sion Was expressed as the percent coe?icient of variation (% 
CV) and the accuracy as the percent difference from the 
theoretical (same as relative error). 
Pharmacokinetic Methods 
Plasma concentration versus time data for HM Were ana 
lyZed using non-compartmental pharmacokinetic methods. 
Maximum plasma concentration (Cmax) and the corre 
sponding sampling time (Tmax) Were identi?ed by observa 
tion. Concentration versus time data Were plotted on a semi 
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logarithmic scale and the terminal log-linear phase Was 
identi?ed by visual inspection. The elimination rate constant 
(e2) Was determined as the slope of the linear regression for 
the terminal log-linear portion of the concentration versus 
time curve. The terminal half-life value (t 1 /2) Was calculated 
as 0.693 divided by e2. 
The area under the curve plotting plasma concentration 
versus curve (AUC) Was calculated by the trapezoidal rule 
and extrapolated to in?nite time. The AUC to the last time 
point (AUCOJm) Was computed by the linear trapeZoidal rule. 
Mean plasma concentration Were calculated for graphical 
presentation only. Data included in the mean calculation Were 
for samples With measurable concentrations draWn Within 5% 
of the nominal sampling time. 
Safety Results 
Results of the clinical measurement of vital signs and body 
Weight exams Were recorded and nasal exams Were per 
formed. A revieW of this data failed to reveal any clinically 
signi?cant safety concerns. There Were no serious adverse 
events and no subjects Were discontinued due to adverse 
effects. Subjects commented that the intensity of the drug 
effects Were loWer With the IN route compared to the IV or IM 
administrations. 
Bioanalytical Results 
Hydromorphone in Plasma by LC/MS/MS Results from 
the control samples and calibration curves analyZed With the 
study samples and the method validation Was reported: The 
overall CV, Which re?ects precision Was <7.4% for the QC 
samples. The percent recovery ranged from 94.5 to 100, 1% 
for QC concentrations 200.0, 500.0, and 1000 Which re?ects 
accuracy Was <6% for the QC samples. 
Pharmacokinetic Results 
The plasma hydromorphone HCL concentrations and 
actual collection times for each of the 9 subjects Was tabulated 
and plasma concentration-time curves for each of the 9 sub 
jects Were prepared. Mean concentration-time curves of 
FIGS. 3 and 4 are representative for most subjects (mean data 
tabulation). FIG. 3 is a plot of the mean (n:9) hydromorphone 
concentration versus time graphs folloWing IV, IM and IN 
doses of 2 mg hydromorphone HCL during the 6 hours after 
dose; FIG. 4 is the same data plotted for 16 hours after the 
dose. Curves for all subjects for 6 hours after the IN dose 
appear in FIG. 5 as a graph of hydromorphone concentrations 
versus time folloWing IN doses of 2 mg hydromorphone HCl 
to 9 subjects. 
Non-compartmental pharmacokinetic analysis Was used to 
evaluate the plasma concentration versus time curves of 
hydromorphone folloWing single 2.0 mg doses of hydromor 
phone HCL by intravenous (IV), intramuscular (IM), and 
intranasal (IN) routes. Individual plasma hydromorphone 
concentrations versus time pro?les for all subjects Were 
recorded; the number of time points used to estimate the 
elimination rate constant Were also recorded; and a complete 
listing of individual and mean pharmacokinetic parameters 
for all 9 subjects Was recorded. 
Rapid absorption of hydromorphone HCl Was observed 
after the IM and IN doses. The Tmax values Were approxi 
mately 9 and 18 minutes, on average, for the IM and IN doses, 
respectively. The mean Tmax for the IV infusion Was not the 
?rst blood sample after the end of the infusion for tWo rea 
sons. The peak concentration after the IV dose in one subject 
Was not at the ?rst blood sample after the end of the IV 
infusion, but at the next time point. In the case of Subject 4, 
acquiring the blood sample immediately folloWing the IV 
infusion Was delayed resulting in the mean Tmax being 
affected. As expected, the hydromorphone Cmax and AUCs 
Were signi?cantly higher after IM and IV administration 
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compared to IN administration. Mean plasma half-lives and 
clearance (after correcting for bioavailability) Were similar 
for all three treatments. 
The arithmetic mean value of absolute bioavailability of 
hydromorphone from the IN formulation is 64%. The range 
Was 50% to 81% bioavailability compared to the IV dose. The 
apparent bioavailability of the IM hydromorphone HCL Was 
about 30% greater than that of the same dose of IV adminis 
tration. The source of this aberrant phenomenon Was not 
found, but unusual distribution phenomena after parenteral 
administration have been reported by others Working in this 
?eld. 
Statistical Evaluation 
The pharmacokinetic parameters in Table 4 Were analyZed 
to evaluate the effect of routes of administration and to test for 
period and sequence effects. The analysis of this pilot data is 
considered in tWo parts: the ?rst part considers only the ?rst 
tWo periods and includes the factors of treatment, sequence 
(i.e., a test of carryover effects) and period; the second part 
contains all three periods and treatments, but ignores the 
effects of sequence and period. The 2-period analysis is noted 
in Table 4 as period 1 vs. 2 and the last column contains the 
3-period model. 
There are even more signi?cant treatment effects for these 
nine outcomes. Post-hoc analyses are based on Fisher’s least 
signi?cant difference procedure and displayed in Table 4. In 
light of the fact that there Were no signi?cant period or 
sequence effects (using an alpha level of 0.05), and since this 
is a pilot project, it is arguable that the above analysis is 
appropriate. 
Since the Cmax value for Subject 07 Was beyond 2 standard 
deviations of the mean With all measurements included, there 
is an objective method for omitting this value for this subject. 
Analyses With and Without this outlier gave the same result. 
TABLE 4 
Summag of signi?cance levels from IN 2-period and 3-period model 
Sequence Period Treatment Treatment 
Parameter (1 vs 2) (1 vs 2) IV vs IM (IV vs IM vs IN) 
Tm“ NS* NS NS .0001 
max NS 0.32 0.71 .0001 
Cmax (omit NS 0.62 NS .0001 
outlier) 
AUCOV, NS NS .0001 .0001 
AUCOVOO NS NS .0001 .0001 
tl/2 NS NS NS NS 
CL/F NS NS .0001 .0001 
Dose NS NS .0001 .0001 
52 NS NS NS NS 
*All p-values reported as NS are >0.1. 
In this study of nine healthy male subjects that received 2 
mg hydromorphone HCL by IV, IM and IN routes, compari 
sons betWeen the IM and IN doses for purposes of bioequiva 
lence could not be completed When it Was found that the 
hydromorphone concentrations for the IM dose Were mark 
edly different as compared to those from the IN doses. 
Noncompar‘tmental analysis of the pharmacokinetic data 
gave results similar to previous studies With respect to half 
lives, clearance, rapid distribution into the tissues, and large 
apparent distribution volume (Parab et al. 1988; Hill et al. 
1991), although comparisons betWeen this study and previous 
studies should be done With caution because of differences in 
analytical techniques. Hydromorphone HCL is Well absorbed 
by the nasal route. Intranasal bioavailability Was approxi 
mately 64%, on average. Interindividual variation Was 
smaller for Cmax and Tmax for the IN route compared to the IV 
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and IM routes. Three compartment characteristics Were sug 
gested by the tri-phasic concentration versus time curves, but 
compartmental analysis Was not performed. 
After the short IV infusion, the hydromorphone concentra 
tions peaked at the end of the infusion as expected in all but 
one subject. Peak concentrations after the IM dose Were unex 
pectedly rapid and precluded the analysis of the data for 
showing the bioequivalence of the IM and IN doses, and that 
analysis Was not pursued. 
Phar'macokinetic parameter estimates yielded CVs less 
than 27% for IN parameters except for VSS (CV 46%). Esti 
mates of Within-subject variability Were smaller than esti 
mates for published studies of IV hydromorphone HCL 
(Parab et al.; Hill et al.; Vallner et al.). Using a crossover 
design and standardizing meal times in this study likely 
helped to loWer Within-subj ect variability. 
Clearance is similar for all three routes of administration 
regardless of route. Variabilities in CL and VSS estimates are 
less after the IV dose compared to the IN dose. The reduced 
variability is expected since IV dosing avoids betWeen-sub 
ject variability in absorption and ?rst-pass metabolism. 
Adverse events Were less frequent and milder after the IN 
dose compared to the IV and IM doses. Assuming a dose 
response relationship, this effect believed to be attributable to 
the fact that the bioavailability of the IN dose Was less and the 
peak concentration loWer, so the subjects effectively received 
a loWer dose that Was more sloWly absorbed. Nasal irritation 
Was not ob served With the exception of a bad taste in the throat 
reported by most subjects after the IN dose. In summary, 
hydromorphone HCL is Well absorbed by the nasal route With 
bioavailability of 64%. Cmax and Tmax Were similar for IM and 
IV routes. Clearance is similar regardless of route. 
Hydromorphone HCL produced no systemic adverse 
events beyond those commonly experienced by injection. 
After single IN doses the subjects complained of bitter taste as 
the only local administration effect of the formulation. The 
bitter taste can be masked by the addition of a sWeetener to the 
formulation. Detailed nasal examination demonstrated no 
pathology of the naso-pharynx after single administration of 
the HM HCL formulations. 
In a further series of studies, hydromorphone HCL is going 
to be administered in accordance With the method of the 
invention as described above to larger groups of volunteers 
selected from the folloWing categories. 
1. in good health, ages 18 to 40; 
. in good health ages 60 to 80; 
. patients With rhinitis; 
. post-partum breast feeding for milk transfer; 
. post-operative pain in Women; 
. children and adolescents With cancer; 
male knee surgery patients; and 
. male and female surgical patients. 
The results of these studies indicate the, HM HCL is suit 
able for use in providing relief from pain in a Wide variety of 
settings Without adverse side effects that are any more sig 
ni?cant than those reported for the alternate routes of admin 
istration, and provides the advantages of convenience, and 
rapid onset. 
Liquid formulations are prepared as fully dissolved solu 
tions in a nasal carrier of each of the folloWing systemic 
analgesics: morphine, apomorphine, metopon, oxymor 
phone, desomorphine, dihydromorphine, levorphanol, cycla 
Zocine, phenaZoeine, levallorphan, 3-hydroxy-N-methyl 
tiaorphinan, levophenacylmorphan, meaZocine, 
norlevorphanol, phenomorphan, nalorphine, nalbuphine, 
buprenorphine, pentaZocine, naloxone, naltrexone, diprenor 
phine, nalmexone, cyprenorphine, alaZoeine, oxilorphan, 
oogamawm 
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cyclorphan, ketobemidone, apocodeine, profadol, cyclor 
phan, cyprenorphine, dihydromorphine, pholcodine, 
hydroxypethidine, fentanyl, sufentanil and alfentanyl. 
Clinical testing of each of the above liquid compositions in 
accordance With the method of the invention as practiced in 
the hydromorphone HCL clinical test using a Pfeiffer unit 
dose applicator produces results comparable to those 
obtained in the hydromorphone HCL Work. 
Example 3 
This example described preferred intranasal compositions 
of the present invention. The opioid can be dissolved in nasal 
carrier that includes a diluent, buffer system, antioxidant, one 
or more agents to control viscosity, and sWeetener, ?avoring 
agent or masking agent. The dosage and volume to be intra 
nasally administered can be adjusted according to patient 
speci?c parameters (for example, Weight, age, kidney and 
liver function, etc.). Preferred agents and ranges of the intra 
nasal compositions are listed beloW and can be selected from 
each group. 
1. Opioid (One or More) 
Hydromorphone HCl 01-30 mg 
Butorphanol tartrate 01-100 mg 
Fentanyl Citrate 5-200 mcg 
Methadone HCl 05-50 mg 
Oxymorphone HCl 01-30 mg 
Morphine HCl 1-40 mg 
2. Buffer (One or More-Optional) 
Sodium citrate 0.01-5% 
Sodium acetate 0.01 -5% 
Sodium phosphate 0.01-5% 
3. Anti-Oxidant (Optional): 
Butylated hydroxytoluene 0.01-5% 
4. SWeetener, ?avoring or masking agent (one or more), 
A sugar, such as sucrose 0.l—5% 
Aspartame 0.l—5% 
Saccharin 0.l—5% 
An oil, such as Wintergreen, orange 0.l—5% 
Menthol and/or camphor 0.1-5% 
5. Viscosity Control (One or More-Optional) 
Methylcellulose 0. l- l 0% 
Carbopol 01-10% 
6. Diluent 
QS With Water or Saline to the Desired Volume 
Having noW generally described the invention, the same 
may be more readily understood through the folloWing refer 
ence to the folloWing example, Which is provided by Way of 
illustration and is not intended to limit the present invention 
unless speci?ed. 
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What is claimed is: 
1. An intranasally deliverable pharmaceutical composition 
comprising: an effective amount of hydromorphone or a phar 
maceutically acceptable salt thereof and a liquid nasal carrier 
that is preservative-free, Wherein the pH of the composition is 
from about 3 to about 6, and Wherein upon intranasal admin 
istration of the composition containing at least 2 mg to about 
10 mg of the hydromorphone or the salt thereof, the subject 
exhibits a Cmax hydromorphone plasma concentration of at 
least about 3000 pg/mL. 
2. An intranasally deliverable pharmaceutical composition 
comprising an effective amount of hydromorphone or a phar 
maceutically acceptable salt thereof, and a preservative-free 
liquid nasal carrier comprising sodium chloride, citric acid, 
and Water, Wherein the pH of the composition is from about 3 
to about 6. 
3. A method of treating a mammal suffering from pain 
comprising intranasally administering to the mammal the 
composition of claim 1 or 2. 
4. The pharmaceutical composition of claim 1 or 2, 
Wherein the liquid nasal carrier comprises a buffering agent. 
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5. The pharmaceutical composition of claim 4, Wherein the 
buffering agent is selected from the group consisting of 
sodium citrate, sodium acetate, sodium phosphate, potassium 
phosphate and mixtures thereof. 
6. The pharmaceutical composition of claim 5, Wherein the 
composition has a pH of about 3 to 5. 
7. The pharmaceutical composition of claim 1 or 2, 
Wherein the buffering agent is present in the composition in a 
total amount of about 0.01% to 3% by Weight. 
8. The pharmaceutical composition of claim 1 or 2, 
Wherein the liquidnasal carrier comprises an aqueous diluent. 
9. The pharmaceutical composition of claim 8, Wherein the 
aqueous diluent is selected from the group consisting of 
saline, Water, dextrose or combinations thereof. 
10. The pharmaceutical composition of claim 1 or 2, 
Wherein the composition has a pH of about 3 to about 5. 
11. The pharmaceutical composition of claim 1 or 2, 
Wherein the composition has a pH of about 3 to about 5. 
12. The pharmaceutical composition of claim 1 or 2, 
Wherein the composition has a pH of about 4. 
* * * * * 
